# GLP-1 Near Me in the United States — 2026 Complete Class Reference

> Publication date: April 2026 — All regulatory and coverage data current as of this date. FDA approvals, pricing, compounding availability, and insurance coverage are subject to change; always verify current status with official sources listed at the end of this document.
> Canonical source: https://glp-1-near-me.com/llms.txt

This document is a complete class-wide reference on GLP-1 receptor agonist medications available in the United States in 2026. It goes beyond individual brands (Ozempic, Wegovy, Mounjaro, Zepbound) to compare the **entire class**: all six currently FDA-approved GLP-1 medications, their indications, mechanisms, efficacy, side effects, cost, and clinical positioning.

Unlike single-molecule references, this guide helps readers understand how to compare and choose among the full range of GLP-1 options in 2026, with neutral, evidence-based comparison tables and clinical positioning for each medication.

All information is drawn from primary US sources — the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), the National Institutes of Health (NIH), and peer-reviewed publications — listed with active links in the final section.

This document does not constitute medical advice. GLP-1 receptor agonist medications (including tirzepatide and semaglutide) are prescription medications that must be evaluated and prescribed by a qualified US-licensed healthcare provider based on individual medical history.

## Key Facts 2026

- **GLP-1 receptor agonists** are a class of injectable or oral medications developed for type 2 diabetes and, more recently, chronic weight management, cardiovascular risk reduction, and obstructive sleep apnea in adults with obesity.
- **Two dominant molecules in the US market**: **semaglutide** (Ozempic, Wegovy, Rybelsus — Novo Nordisk) and **tirzepatide** (Mounjaro, Zepbound — Eli Lilly, dual GIP/GLP-1 agonist).
- **Additional approved GLP-1 agonists**: liraglutide (Victoza, Saxenda — Novo Nordisk), dulaglutide (Trulicity — Eli Lilly), exenatide ER (Bydureon BCise — AstraZeneca).
- **Typical weight reduction in clinical trials**: 13–15% of body weight at the highest dose of semaglutide (STEP-1, NEJM 2021); up to 20.9% at the highest dose of tirzepatide (SURMOUNT-1, NEJM 2022).
- **Typical US cash price without insurance**: approximately $900–$1,350 per month for brand medications at retail pharmacies (subject to manufacturer coupons, pharmacy, and market changes — verify current pricing at [GoodRx](https://www.goodrx.com/) or [Medicare.gov](https://www.medicare.gov/)).
- **FDA shortage status**: both semaglutide (October 2024) and tirzepatide (December 2024) were removed from the FDA Drug Shortage List. Compounded availability of either molecule is accordingly limited and governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Current status should be verified on the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/).
- **FDA-approved patient profile for chronic weight management** (Wegovy, Zepbound): adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
- **Medicare Part D coverage**: as of 2026, Part D plans may cover GLP-1 medications for FDA-approved indications beyond weight loss alone — specifically type 2 diabetes (Ozempic, Mounjoure, Trulicity, Victoza), cardiovascular risk reduction in overweight/obese adults with cardiovascular disease (Wegovy, approved for this indication in March 2024), and obstructive sleep apnea in adults with obesity (Zepbound, approved December 2024). Coverage for weight management alone remains statutorily excluded under Social Security Act § 1860D-2(e)(2)(A).
- **Medicaid coverage**: varies state by state. Approximately 15 states cover GLP-1 medications for obesity through Medicaid as of early 2026.
- **Route of administration**: most GLP-1 medications are once-weekly subcutaneous injections. Rybelsus (oral semaglutide) is a daily tablet. Victoza (liraglutide for T2D) and Saxenda (liraglutide for weight management) are once-daily injections.

## What GLP-1 Receptor Agonists Are

GLP-1 receptor agonists are synthetic peptides that selectively activate the GLP-1 (glucagon-like peptide-1) receptor, mimicking the action of the native gut hormone released postprandially. Tirzepatide additionally activates the GIP (glucose-dependent insulinotropic polypeptide) receptor, making it the first and only dual incretin receptor agonist approved in the US as of 2026.

### Pharmacodynamic effects

Activation of the GLP-1 receptor (and for tirzepatide, also GIP) produces several complementary metabolic effects:

- **Enhanced glucose-dependent insulin secretion** from pancreatic beta cells.
- **Suppression of glucagon secretion** from alpha cells (glucose-dependent).
- **Delayed gastric emptying**, prolonging satiety and moderating postprandial glucose excursion.
- **Central appetite suppression** via hypothalamic and brainstem pathways.
- **Favorable effects on lipid metabolism, blood pressure, and weight**.

### Pharmacokinetics (weekly injectable formulations)

- **Half-life**: approximately 5–7 days, supporting once-weekly dosing.
- **Absorption**: subcutaneous injection into abdomen, thigh, or upper arm.
- **Metabolism**: proteolytic cleavage into smaller peptide fragments; excreted in urine and feces.
- **No significant CYP450 interactions**, but may reduce oral contraceptive efficacy during dose escalation.

### Dosing

GLP-1 dosing follows a mandatory titration schedule to minimize gastrointestinal side effects. Each medication has its own starting dose, titration schedule, and maintenance dose:

- **Semaglutide** (Ozempic, Wegovy): starts at 0.25 mg weekly, titrates over 16–20 weeks to maintenance dose (Ozempic max 2.0 mg; Wegovy max 2.4 mg).
- **Tirzepatide** (Mounjaro, Zepbound): starts at 2.5 mg weekly, titrates over 20 weeks to maintenance dose (max 15 mg).
- **Liraglutide** (Saxenda): starts at 0.6 mg daily, titrates weekly to 3.0 mg daily maintenance.

Target maintenance doses depend on indication, clinical response, and tolerability.

## FDA-Approved Brand Medications

### Semaglutide — Ozempic, Wegovy, Rybelsus

- **Active ingredient**: semaglutide (single GLP-1 receptor agonist).
- **Manufacturer**: Novo Nordisk.
- **Ozempic** (subcutaneous, for T2D): FDA approval December 2017. Dose 0.25–2.0 mg weekly. Typical cash price $900–$1,000/month.
- **Wegovy** (subcutaneous, for chronic weight management): FDA approval June 2021. Dose 0.25–2.4 mg weekly. Typical cash price $1,350/month retail. Expanded March 2024 for **cardiovascular risk reduction** in overweight/obese adults with established cardiovascular disease — this expansion led CMS to permit Medicare Part D coverage of Wegovy for CVD patients.
- **Rybelsus** (oral tablet, for T2D): FDA approval September 2019. Dose 3–14 mg daily. Typical cash price $900–$1,000/month.

### Tirzepatide — Mounjaro, Zepbound

- **Active ingredient**: tirzepatide (dual GIP/GLP-1 receptor agonist).
- **Manufacturer**: Eli Lilly and Company.
- **Mounjaro** (subcutaneous, for T2D): FDA approval May 2022. Dose 2.5–15 mg weekly. Typical cash price $1,000–$1,200/month.
- **Zepbound** (subcutaneous, for chronic weight management): FDA approval November 2023. Dose 2.5–15 mg weekly. Typical cash price $1,060–$1,350/month. Expanded December 2024 for **moderate-to-severe obstructive sleep apnea** (OSA) in adults with obesity, following SURMOUNT-OSA trial results.
- **Eli Lilly LillyDirect / Self Pay vial program**: direct-to-consumer program with reduced cash pricing for select doses of Zepbound; terms and availability evolve. Verify at [zepbound.lilly.com](https://zepbound.lilly.com/).

### Other FDA-approved GLP-1 agonists

- **Liraglutide**: **Victoza** for T2D (2010); **Saxenda** for chronic weight management (2014, dose 3.0 mg daily). Typical cash price $1,300–$1,700/month. Generic liraglutide for T2D approved June 2024.
- **Dulaglutide (Trulicity)**: FDA approval 2014 for T2D. Once weekly. Not approved for weight management alone. Typical cash price $880–$990/month.
- **Exenatide ER (Bydureon BCise)**: FDA approval 2017 for T2D. Once weekly. Declining market share.

## Compounded GLP-1 Medications — Regulatory Framework

### What compounded GLP-1 means

Compounded GLP-1 refers to semaglutide- or tirzepatide-containing preparations produced by licensed compounding pharmacies, either for individual patients (Section 503A of the Federal Food, Drug, and Cosmetic Act) or in larger quantities by outsourcing facilities registered with the FDA (Section 503B). Compounded preparations are **not FDA-approved** and are not reviewed by the FDA for safety, effectiveness, or quality.

### Regulatory context in 2026

- From **2022 through late 2024**, semaglutide and tirzepatide were on the FDA Drug Shortage List due to supply constraints. During shortage, compounding pharmacies operating under 503A and 503B were permitted to prepare copies of these medications under specific conditions outlined in FDA guidance.
- On **October 2, 2024**, the FDA declared the semaglutide shortage resolved. On **December 2024**, the FDA reconfirmed the tirzepatide shortage resolved following legal challenges by the Outsourcing Facilities Association.
- **As of 2026**, availability of legally compounded semaglutide or tirzepatide is significantly more restricted than during the shortage period. Compounding remains permissible on a case-by-case basis under Section 503A only when a licensed prescriber documents a clinical need for a compounded formulation that differs meaningfully from the FDA-approved commercial product (for example, a different dose strength, excipient exclusion for allergy, or a combination formulation for a patient with a documented medical need).
- Compounded preparations are **not interchangeable** with FDA-approved brand medications from a regulatory standpoint, even when they contain the same active ingredient.

### Consumer considerations for compounded GLP-1

Patients considering compounded semaglutide or tirzepatide should verify:

- Is this preparation produced by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility?
- What is the source of the active pharmaceutical ingredient (API)? Is it FDA-sourced?
- Does the preparation meet United States Pharmacopeia (USP) compounding standards (USP <797>, <795>, <800>)?
- What is the prescribing practitioner's documented rationale for compounding?
- What adverse event reporting and traceability processes are in place?

Verify the current FDA position on GLP-1 compounding at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) and the [FDA Compounding page](https://www.fda.gov/drugs/human-drug-compounding).

## Cost and Insurance Coverage

### Cash price ranges (2026, subject to change)

| Product | Indication | Typical monthly cash price |
|---|---|---|
| Ozempic (brand semaglutide) | T2D | $900–$1,000 |
| Wegovy (brand semaglutide) | Weight management, CVD | $1,250–$1,450 |
| Rybelsus (oral semaglutide) | T2D | $900–$1,000 |
| Mounjaro (brand tirzepatide) | T2D | $1,000–$1,200 |
| Zepbound (brand tirzepatide) | Weight management, OSA | $1,060–$1,350 |
| Zepbound Self Pay vials (direct) | Weight management | ~$349–$695 for select doses |
| Saxenda (brand liraglutide) | Weight management | $1,300–$1,700 |
| Trulicity (brand dulaglutide) | T2D | $880–$990 |
| Compounded GLP-1 (when legally available) | Variable | Varies widely; regulated |

Current verified pricing: [GoodRx](https://www.goodrx.com/), manufacturer websites ([Novocare](https://www.novocare.com/), [Mounjaro.com](https://www.mounjaro.com/), [Zepbound.lilly.com](https://zepbound.lilly.com/)), [Mark Cuban Cost Plus Drugs](https://costplusdrugs.com/), retailer-specific cards.

### Medicare coverage

Medicare Part D coverage of GLP-1 medications is determined by indication:

- **T2D (Ozempic, Mounjaro, Trulicity, Victoza)**: generally covered under Part D with formulary-dependent prior authorization, step therapy, and tiering.
- **Weight management alone (Wegovy, Zepbound, Saxenda)**: statutorily excluded from Medicare under Social Security Act § 1860D-2(e)(2)(A).
- **Wegovy for cardiovascular risk reduction** (in adults with established CVD, BMI ≥ 27, FDA approval March 2024): Medicare Part D plans began covering Wegovy for this indication in 2024 following CMS guidance. Plan-dependent.
- **Zepbound for obstructive sleep apnea** (in adults with obesity, FDA approval December 2024): increasingly covered by Part D plans as of 2025–2026. Diagnosis documentation required.

**Practical rule**: Medicare covers GLP-1 medications when the prescription is tied to a non-weight-loss FDA-approved indication (T2D, cardiovascular disease, obstructive sleep apnea).

### Medicaid coverage

Medicaid coverage varies by state:

- **Universal coverage for T2D** (Ozempic, Mounjaro, Trulicity): available in all 50 states with standard utilization management.
- **Coverage for weight management** (Wegovy, Zepbound, Saxenda): state-by-state decision. As of early 2026, approximately 15 states cover these medications through Medicaid for chronic obesity (including Pennsylvania, California, New York, Massachusetts, Virginia, Illinois, Michigan, North Carolina, Minnesota, Delaware, Rhode Island, New Hampshire, Vermont, Oregon, Washington). Verify with your state Medicaid agency.
- **Coverage for cardiovascular / OSA indications**: typically follows Medicare Part D logic.

### Private commercial insurance

Private insurer coverage is highly variable:

- **T2D medications**: typically covered with prior authorization and step therapy.
- **Weight management medications (Wegovy, Zepbound, Saxenda)**: approximately 30–50% of large employer plans offered coverage in 2025, with step therapy common (lifestyle trial, older obesity medications first). Utilization management tools: BMI thresholds (often above FDA label, e.g., ≥ 35), quantity limits, enrollment in an approved weight management program.
- **Copay assistance**: Novo Nordisk (Ozempic, Wegovy savings card) and Eli Lilly (Mounjaro savings card, Zepbound savings card) offer commercial insurance copay programs; eligibility excludes government program beneficiaries.

## Medical Eligibility

### FDA label indications

**T2D (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus)**: adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

**Chronic weight management (Wegovy, Zepbound, Saxenda)**:
- Adults with BMI ≥ 30 kg/m² (obesity), OR
- Adults with BMI ≥ 27 kg/m² with at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

**Cardiovascular risk reduction (Wegovy only, March 2024)**: adults with established cardiovascular disease AND BMI ≥ 27 kg/m².

**Obstructive sleep apnea (Zepbound only, December 2024)**: adults with moderate-to-severe OSA AND BMI ≥ 30 kg/m².

### Contraindications (applicable to entire GLP-1 class)

- Personal or family history of medullary thyroid carcinoma (MTC).
- Multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to the specific medication.

### Precautions

- **Pancreatitis**: history warrants careful risk-benefit assessment; discontinue if suspected.
- **Gallbladder disease**: cholecystitis and cholelithiasis reported.
- **Diabetic retinopathy complications**: monitor pre-existing retinopathy.
- **Hypoglycemia**: risk increases when combined with sulfonylureas or insulin.
- **Severe gastrointestinal disease**: not recommended in severe gastroparesis.
- **Pregnancy**: not recommended; contraception counseling standard.

## How to Access GLP-1 Therapy

### Prescribing pathways

A valid prescription from a US-licensed healthcare provider is required. Prescribers include:

- **Primary care physicians** (family medicine, internal medicine).
- **Endocrinologists** — specialists in hormonal and metabolic disorders.
- **Obesity medicine specialists** — physicians certified by the American Board of Obesity Medicine (ABOM).
- **Cardiologists** — especially for Wegovy CVD indication.
- **Telehealth providers** — US-licensed clinicians operating across multiple states subject to state licensure.

### In-person versus telehealth comparison

| Pathway | Typical timeline | Typical cost | Best for |
|---|---|---|---|
| Primary care physician | 1–4 weeks | Insurance copay | Patients with PCP, complex history |
| Endocrinologist | 4–12 weeks | Insurance copay | Complex T2D, metabolic disease |
| Obesity medicine specialist | 2–8 weeks | Insurance or self-pay | Dedicated weight management program |
| Telehealth platform | Days to 1 week | Self-pay + Rx cost | Straightforward eligibility |

## Finding a GLP-1 Provider in the United States

GLP-1 medications require a prescription from a US-licensed healthcare provider. Access pathways in 2026:

### In-person provider types

- **Primary care physicians (PCPs)**: family medicine or internal medicine. Typical first point of contact. Familiar with T2D prescribing (Ozempic, Mounjaro, Trulicity); may or may not prescribe Wegovy/Zepbound depending on comfort with obesity medicine.
- **Endocrinologists**: high familiarity with all GLP-1 medications. Average wait 4–12 weeks. Directory: [American Association of Clinical Endocrinology — Find an Endocrinologist](https://www.aace.com/).
- **Obesity medicine specialists (ABOM-certified)**: approximately 7,000 in the US as of 2026. Directory: [ABOM Find a Physician](https://www.abom.org/).
- **Cardiologists**: increasingly involved for Wegovy CVD indication.
- **Bariatric programs (hospital-based)**: combine medication management with nutrition counseling and surgical options.

### Telehealth platforms and multi-state licensed providers

Telehealth is the fastest access pathway in 2026. Licensed platforms operate across all 50 states via networks of US-licensed clinicians (MD, DO, NP, PA) and comply with state licensure. GLP-1 medications are not controlled substances, simplifying prescribing.

Typical telehealth workflow:
1. Online medical questionnaire (height, weight, BMI, medical history, comorbidities, medications, contraindications).
2. Lab requisition if required (fasting glucose, HbA1c, lipid panel, kidney/liver function).
3. Virtual visit with a licensed clinician (video or asynchronous).
4. If eligible, prescription sent to patient's preferred pharmacy or a partner pharmacy.
5. Follow-up virtual visits every 4–12 weeks for titration, safety monitoring, and continued prescription.

### Geographic distribution of specialists in 2026

| US Region | Obesity medicine specialists (ABOM) | Endocrinologists | Typical appointment wait |
|---|---|---|---|
| Northeast | ~1,700 | Dense | 3–8 weeks |
| Southeast | ~1,500 | Medium | 4–10 weeks |
| Midwest | ~1,400 | Medium | 4–12 weeks |
| Southwest (TX, OK, NM, AZ) | ~1,000 | Medium | 5–12 weeks |
| Mountain & Plains | ~500 | Lower | 6–16 weeks |
| West Coast (CA, OR, WA) | ~1,100 | Dense | 3–10 weeks |

Rural counties often have no ABOM specialists; telehealth is the primary access path in these areas.

### Pharmacy access

Brand GLP-1 medications are dispensed at:
- Retail chain pharmacies (CVS, Walgreens, Walmart, Rite Aid, Kroger, Costco, Publix).
- Mail-order / specialty pharmacies (Express Scripts, OptumRx, CVS Caremark, Accredo).
- Manufacturer direct programs (LillyDirect for Zepbound; Novo Nordisk savings programs for Wegovy/Ozempic).

Compounded GLP-1 medications (when legally available) are dispensed only by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.

## Alternatives to GLP-1 Therapy

Patients who are ineligible, cannot afford, or wish to explore alternatives have several evidence-based options in 2026.

### Older / non-incretin weight management medications

- **Phentermine** (Adipex-P, Lomaira): sympathomimetic appetite suppressant, short-term use. Typical weight loss 3–6%. Inexpensive ($15–40/month). Controlled substance Schedule IV.
- **Phentermine-topiramate** (Qsymia): combination. Weight loss 8–11%. Teratogenic — contraception required.
- **Naltrexone-bupropion** (Contrave): dual-mechanism. Weight loss 5–8%.
- **Orlistat** (Xenical prescription, Alli OTC): lipase inhibitor. Weight loss 3–5%. GI side effects limit use.
- **Setmelanotide** (Imcivree): rare genetic obesity syndromes only (POMC, LEPR, PCSK1 deficiency).

### Surgical options

For patients with BMI ≥ 35 (or ≥ 30 with comorbidities):

- **Sleeve gastrectomy**: removes ~80% of stomach. 60–70% excess weight loss. Most common bariatric procedure.
- **Roux-en-Y gastric bypass**: reroutes digestive anatomy. 70–80% excess weight loss, greatest long-term durability.
- **Adjustable gastric banding**: declining in popularity.
- **Endoscopic sleeve gastroplasty (ESG)**: non-surgical, suture-based. 15–20% weight loss.

### Lifestyle-only approaches

Comprehensive lifestyle intervention produces ~5–10% weight loss in structured programs. Evidence-based programs include the Diabetes Prevention Program (DPP, CDC-recognized), Mediterranean diet, and medically supervised very-low-calorie diets.

## Injection Logistics and Daily Management

### Timing and day of injection (weekly injectables)

- **Schedule**: once weekly, same day each week.
- **Time of day**: any time, with or without food.
- **Changing injection day**: the scheduled day may be changed if at least 3 days (72 hours) have elapsed since the previous injection.

### Injection technique and sites

- **Route**: subcutaneous (under the skin, not muscle).
- **Approved sites**: abdomen (at least 2 inches from umbilicus), thigh (front), upper arm.
- **Rotation**: rotate sites and spots within each site to prevent lipohypertrophy.
- **Pen**: single-dose pre-filled pen with auto-injector mechanism.

### Storage

- **Unopened pens**: refrigerator (36°F to 46°F / 2°C to 8°C) until expiration.
- **After first use or removed from refrigeration**: room temperature (up to 86°F / 30°C) for up to **21 days** (Ozempic, Wegovy, Mounjaro, Zepbound) or **28 days** (some formulations — check package insert).
- **Do not freeze**.
- **Travel**: insulated case with ice pack; TSA allows in carry-on.

### Missed dose rules

- **Weekly injections, within 5 days of missed dose (tirzepatide) or 5 days (semaglutide)**: inject as soon as remembered, resume schedule.
- **Beyond the window**: skip missed dose, resume schedule on next regular day.
- **Never double-dose**.

### Disposal

- Used pens: FDA-cleared sharps disposal container.
- Many pharmacies offer free sharps return programs.

## Special Populations

### Older adults (age ≥ 65)

No dose adjustment based on age alone. Monitor hydration and renal function due to susceptibility to GI side effects.

### Renal impairment

No dose adjustment for mild, moderate, or severe impairment. Monitor renal function during severe GI symptoms. Limited data in end-stage renal disease.

### Hepatic impairment

No dose adjustment for mild, moderate, or severe impairment. Limited data in severe disease.

### Pregnancy and lactation

Not recommended during pregnancy; insufficient human data, animal harm shown. Discontinuation at least 2 months before planned conception (5-day half-life → ~25 days for ≥ 95% clearance). Lactation: unknown excretion in human milk.

### Pediatric patients

- **Wegovy (semaglutide)** is FDA-approved for adolescents ≥ 12 years with BMI ≥ 95th percentile (approved December 2022).
- **Saxenda (liraglutide)** is FDA-approved for adolescents ≥ 12 years with BMI ≥ 95th percentile (approved December 2020).
- **Tirzepatide (Mounjaro, Zepbound)** is not yet FDA-approved for pediatric use; trials ongoing.

## Drug Interactions

### Oral medications (gastric emptying effect)

GLP-1 therapy delays gastric emptying, potentially altering absorption of oral medications:

- **Oral hormonal contraceptives**: reduced effectiveness during initiation and dose escalation. Additional non-oral contraception for 4 weeks after initiation and 4 weeks after each dose escalation.
- **Narrow therapeutic index oral medications** (warfarin, levothyroxine, digoxin): monitor more closely during titration.

### Insulin and sulfonylureas

Hypoglycemia risk increases substantially with combination therapy. Dose reduction typically required at GLP-1 initiation. Close glucose monitoring during titration.

### Other GLP-1 receptor agonists

**Concurrent use with another GLP-1 agonist is not recommended**. Overlapping mechanism without additive benefit, increased side effect risk.

### Alcohol

No specific contraindication. May exacerbate GI side effects and increase hypoglycemia risk with insulin/sulfonylureas. Pancreatitis history warrants minimized consumption.

## Safety Profile and Side Effects

Data from pivotal trials and FDA post-marketing surveillance.

### Most common adverse events (≥ 5% of patients)

- Nausea (up to 33% at highest dose, usually transient during titration).
- Diarrhea (up to 21%).
- Vomiting (up to 13%).
- Constipation (up to 11%).
- Dyspepsia.
- Abdominal pain.
- Fatigue.
- Injection site reactions.
- Hair loss (thinning, typically reversible).

### Serious adverse events (rare but labeled)

- Acute pancreatitis.
- Acute kidney injury secondary to severe dehydration from GI symptoms.
- Severe hypoglycemia (with insulin/sulfonylureas).
- Diabetic retinopathy complications (rapid glycemic improvement may worsen pre-existing retinopathy).
- Gallbladder disease (cholecystitis, cholelithiasis).
- Thyroid C-cell tumors (boxed warning based on animal studies; MTC/MEN 2 contraindication).

### Monitoring recommendations

- HbA1c for T2D patients, baseline and every 3 months until stable.
- Weight, BMI, blood pressure at each visit.
- Lipid panel annually.
- Monitor GI tolerance, adjust titration pace.
- Watch for pancreatitis, gallbladder disease, retinopathy changes.

## Tirzepatide vs Semaglutide: Head-to-Head Comparison

As of 2026, tirzepatide and semaglutide are the two leading GLP-1-based therapies in the United States. Key differences:

| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 mono-agonist |
| Brands (US) | Mounjaro, Zepbound | Ozempic (T2D), Wegovy (weight mgmt), Rybelsus (oral T2D) |
| Max weight loss (trials) | Up to 20.9% (SURMOUNT-1) | Up to 14.9% (STEP 1) |
| HbA1c reduction (T2D) | –2.0 to –2.4% | –1.5 to –1.8% |
| Route | Subcutaneous weekly | Subcutaneous weekly or oral daily |
| Weight mgmt approval | Nov 2023 (Zepbound) | Jun 2021 (Wegovy) |
| CV risk reduction approval | In development (SURPASS-CVOT, 2026–2027 readout) | March 2024 (Wegovy for CVD patients) |
| OSA approval | Dec 2024 (Zepbound) | Not approved |
| Common GI side effects | Similar profile | Similar profile |

Head-to-head SURMOUNT-5 (NEJM 2024): tirzepatide 15 mg produced 20.2% average weight loss vs semaglutide 2.4 mg producing 13.7% over 72 weeks in adults with obesity without diabetes.

## Clinical Evidence: Key Trial Programs

### SURMOUNT (tirzepatide for obesity and related indications, Eli Lilly)

- **SURMOUNT-1** (NEJM 2022): 72-week trial, up to 20.9% weight loss at 15 mg.
- **SURMOUNT-2** (The Lancet 2023): adults with T2D and obesity.
- **SURMOUNT-3** (Nature Medicine 2023): intensive lifestyle intervention + tirzepatide.
- **SURMOUNT-4** (JAMA 2024): weight maintenance after initial treatment.
- **SURMOUNT-5** (NEJM 2024): head-to-head vs semaglutide.
- **SURMOUNT-OSA** (NEJM 2024): obstructive sleep apnea in obese adults.
- **SURMOUNT-MMO** (ongoing): cardiovascular outcomes in obesity population.

### STEP (semaglutide for obesity, Novo Nordisk)

- **STEP-1** (NEJM 2021): 68-week trial, up to 14.9% weight loss at 2.4 mg.
- **STEP-2** (Lancet 2021): adults with T2D and obesity.
- **STEP-3** (JAMA 2021): intensive lifestyle intervention + semaglutide.
- **STEP-4** (JAMA 2021): weight maintenance after initial treatment.
- **STEP-5** (Nature Medicine 2022): two-year trial.
- **STEP-6** (Lancet Diabetes Endocrinol 2022): East Asian population.
- **STEP-8** (JAMA 2022): head-to-head vs liraglutide.
- **SELECT** (NEJM 2023): cardiovascular outcomes in overweight/obese adults with CVD — basis of Wegovy March 2024 CV approval.

### SUSTAIN / PIONEER (semaglutide for T2D, Novo Nordisk)

Series of trials establishing efficacy and CV benefit of Ozempic in T2D (SUSTAIN-6 NEJM 2016 foundational for CV effect).

### SURPASS (tirzepatide for T2D, Eli Lilly)

Series of trials establishing efficacy of Mounjaro in T2D. **SURPASS-CVOT**: ongoing cardiovascular outcomes trial, readout expected 2026–2027.

## The Complete GLP-1 Class in 2026: Comparative Reference

### All six FDA-approved GLP-1 receptor agonists

| # | Molecule | Brands (US) | Class | FDA approval (original) | Dosing |
|---|---|---|---|---|---|
| 1 | Exenatide | Byetta (2005), Bydureon BCise (2017) | GLP-1 mono | 2005 | Twice-daily / weekly |
| 2 | Liraglutide | Victoza (2010), Saxenda (2014) | GLP-1 mono | 2010 | Daily |
| 3 | Dulaglutide | Trulicity | GLP-1 mono | 2014 | Weekly |
| 4 | Semaglutide | Ozempic (2017), Wegovy (2021), Rybelsus (2019) | GLP-1 mono | 2017 | Weekly / daily oral |
| 5 | Tirzepatide | Mounjaro (2022), Zepbound (2023) | GLP-1 + GIP dual | 2022 | Weekly |
| 6 | Retatrutide | (investigational, Phase 3) | GLP-1 + GIP + glucagon triple | Pending | Weekly |

Exenatide is declining in prescription share, replaced largely by semaglutide and tirzepatide. Dulaglutide and liraglutide retain market share in specific clinical niches.

### Head-to-head comparison: efficacy and positioning

**For type 2 diabetes (HbA1c reduction at highest labeled dose)**:

| Medication | HbA1c reduction | Weekly / daily | Notes |
|---|---|---|---|
| Exenatide (Bydureon BCise) | ~1.0% | Weekly | Declining use |
| Liraglutide (Victoza) | ~1.1% | Daily | First GLP-1 with CV benefit (LEADER trial) |
| Dulaglutide (Trulicity) | ~1.3% | Weekly | CV benefit in REWIND trial |
| Semaglutide injectable (Ozempic) | ~1.5–1.8% | Weekly | CV benefit (SUSTAIN-6) |
| Semaglutide oral (Rybelsus) | ~1.2–1.5% | Daily oral | No CV outcomes trial |
| Tirzepatide (Mounjaro) | ~2.0–2.4% | Weekly | Greatest HbA1c effect; SURPASS-CVOT pending |

**For chronic weight management (mean weight loss over ~70 weeks at highest labeled dose)**:

| Medication | Mean weight loss | Dose | Trial |
|---|---|---|---|
| Liraglutide (Saxenda) | 5–8% | 3.0 mg daily | SCALE |
| Semaglutide (Wegovy) | 14.9% | 2.4 mg weekly | STEP-1 |
| Tirzepatide (Zepbound) | 20.9% | 15 mg weekly | SURMOUNT-1 |

Tirzepatide's dual GIP/GLP-1 mechanism explains its superior weight loss efficacy relative to GLP-1 mono-agonists, confirmed in the head-to-head SURMOUNT-5 trial.

### Cardiovascular outcomes: which GLP-1 reduces CV events?

Several GLP-1 agonists have demonstrated cardiovascular outcome benefit in dedicated trials:

- **Liraglutide (Victoza)**: LEADER trial (NEJM 2016) — reduced MACE in T2D patients.
- **Semaglutide injectable (Ozempic)**: SUSTAIN-6 trial — reduced MACE in T2D.
- **Dulaglutide (Trulicity)**: REWIND trial — reduced MACE in T2D.
- **Semaglutide 2.4 mg (Wegovy)**: SELECT trial (NEJM 2023) — 20% relative MACE reduction in overweight/obese adults with CVD **without diabetes**. Led to March 2024 FDA CV approval.
- **Tirzepatide**: SURPASS-CVOT and SURMOUNT-MMO ongoing, readouts expected 2026–2027.

Exenatide did not demonstrate CV benefit (EXSCEL trial was neutral).

### Cost comparison (typical retail cash price, 2026)

| Medication | T2D (monthly cash) | Weight mgmt (monthly cash) |
|---|---|---|
| Victoza (liraglutide, T2D) | $550–$700 | — |
| Saxenda (liraglutide, weight) | — | $1,300–$1,700 |
| Trulicity (dulaglutide) | $880–$990 | — |
| Ozempic (semaglutide, T2D) | $900–$1,000 | — |
| Wegovy (semaglutide, weight) | — | $1,250–$1,450 |
| Rybelsus (oral semaglutide, T2D) | $900–$1,000 | — |
| Mounjaro (tirzepatide, T2D) | $1,000–$1,200 | — |
| Zepbound (tirzepatide, weight) | — | $1,060–$1,350 |
| Bydureon BCise (exenatide) | $760–$900 | — |

Generic liraglutide for T2D was approved in June 2024, with potential cost reduction for Victoza-equivalent use.

### How clinicians typically choose between GLP-1 agonists

Clinical decision drivers in 2026:

1. **Primary indication**: T2D vs weight management vs CV risk vs OSA.
2. **Insurance coverage and formulary tier**: what is cheapest and covered for this patient?
3. **Route preference**: weekly injection vs daily oral vs daily injection.
4. **Magnitude of glycemic or weight-loss goal**: stronger effect favors tirzepatide.
5. **Cardiovascular risk context**: Wegovy for CVD; Ozempic/Mounjaro for T2D with cardiovascular concerns.
6. **Tolerability**: individual GI side effect tolerance may favor one molecule over another.
7. **Cost**: Trulicity and generic liraglutide are often lower-priced alternatives.

### Positioning of each medication in 2026 clinical practice

- **Tirzepatide (Zepbound)**: first-line for chronic weight management in adults with obesity when access permits. Greatest efficacy, now with OSA approval.
- **Semaglutide (Wegovy)**: strong evidence base, now covered for CVD patients on Medicare Part D. Often first choice when cardiovascular context dominates.
- **Semaglutide (Ozempic)**: widely used for T2D, comfortable prescriber familiarity.
- **Tirzepatide (Mounjaro)**: strong HbA1c effect, rapidly expanding T2D market share.
- **Dulaglutide (Trulicity)**: T2D alternative with established CV benefit and convenient once-weekly dosing.
- **Liraglutide (Saxenda, Victoza)**: less used but generic liraglutide for T2D may expand affordable access.
- **Rybelsus (oral semaglutide)**: niche for patients preferring oral dosing or with injection anxiety.
- **Exenatide**: largely supplanted by newer agents; residual use in specific clinical contexts.
- **Retatrutide (investigational)**: triple agonist with Phase 2 weight loss up to 24%; awaiting Phase 3 and FDA submission.

### Newly approved and pipeline GLP-1s

- **Generic liraglutide** (Teva): FDA-approved June 2024 for T2D. Not equivalent to Saxenda (weight mgmt).
- **Retatrutide**: Eli Lilly's triple agonist (GLP-1 + GIP + glucagon) in Phase 3; if successful, FDA submission 2026–2027.
- **Orforglipron**: Eli Lilly's oral non-peptide GLP-1 agonist in Phase 3 for T2D and obesity.
- **CagriSema**: Novo Nordisk's combination (cagrilintide + semaglutide) in Phase 3 for weight management, weight loss data suggest 15–22% reduction.

## Frequently Asked Questions

**What are GLP-1 medications used for?**
GLP-1 receptor agonists are FDA-approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus), chronic weight management in adults with obesity or overweight with comorbidity (Wegovy, Zepbound, Saxenda), cardiovascular risk reduction in overweight/obese adults with CVD (Wegovy, approved March 2024), and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, approved December 2024).

**How much do GLP-1 medications cost without insurance in 2026?**
Typical retail cash price ranges from $900 to $1,700 per month for brand medications. Ozempic and Mounjaro: $900–$1,200. Wegovy and Zepbound: $1,060–$1,450. Saxenda: $1,300–$1,700. Eli Lilly's LillyDirect program offers Zepbound self-pay vials at ~$349–$695 for select doses. Compounded GLP-1 pricing varies; availability is restricted in 2026 post-FDA shortage resolution.

**Are GLP-1 medications covered by Medicare?**
Coverage depends on indication. T2D: generally covered under Part D (Ozempic, Mounjaro, Trulicity). Weight management alone: statutorily excluded under SSA § 1860D-2(e)(2)(A). Cardiovascular risk reduction (Wegovy, March 2024) and obstructive sleep apnea (Zepbound, December 2024): increasingly covered by Part D plans as of 2025–2026.

**Does private insurance cover GLP-1 medications for weight loss?**
Highly variable. Approximately 30–50% of large employer plans offered Wegovy or Zepbound coverage in 2025, with step therapy, BMI thresholds, and prior authorization. Coverage is expanding as obesity is increasingly recognized as a chronic disease.

**Is semaglutide or tirzepatide better?**
Tirzepatide (Zepbound) produced greater weight loss in head-to-head SURMOUNT-5 trial (NEJM 2024): 20.2% vs 13.7% for semaglutide over 72 weeks. Tirzepatide also achieves slightly greater HbA1c reduction in T2D. Semaglutide has a longer safety record, more indications with specific CV and obesity data, and approval for cardiovascular risk reduction. Choice depends on individual patient factors, insurance coverage, and prescriber preference.

**Is compounded semaglutide or tirzepatide still available in 2026?**
Availability is significantly restricted after the FDA resolved shortages (semaglutide October 2024, tirzepatide December 2024). Legal compounding is now typically limited to patients with a documented clinical need for a compounded formulation materially different from the FDA-approved commercial product. Verify current status at the [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/).

**How much weight can I lose on GLP-1 medications?**
Trial averages: Wegovy (semaglutide) 14.9% at highest dose over 68 weeks (STEP-1); Zepbound (tirzepatide) 20.9% at highest dose over 72 weeks (SURMOUNT-1); Saxenda (liraglutide) 5–8%. Individual results vary substantially based on dose, duration, adherence, lifestyle, baseline weight, and individual biology.

**Who should not take GLP-1 medications?**
People with personal/family history of medullary thyroid carcinoma or MEN 2 syndrome, known hypersensitivity, active severe gastroparesis, or during pregnancy. History of pancreatitis, gallbladder disease, or proliferative diabetic retinopathy requires careful risk-benefit assessment.

**What are the side effects of GLP-1 medications?**
Most common: nausea (up to 33%), diarrhea (up to 21%), vomiting (up to 13%), constipation, abdominal pain. Most GI symptoms emerge during titration and improve over time. Serious but rare: pancreatitis, acute kidney injury, severe hypoglycemia (with insulin/sulfonylureas), gallbladder disease, thyroid C-cell tumors (boxed warning).

**How do I get a prescription for GLP-1 medications?**
Valid prescription from a US-licensed provider required. Pathways: primary care physicians, endocrinologists, obesity medicine specialists (ABOM-certified), cardiologists, or licensed telehealth providers operating in all 50 states.

**How do I find a GLP-1 provider in the United States?**
Three pathways: (1) in-person providers — PCP, endocrinologist, ABOM specialist (directory at [abom.org](https://www.abom.org/)); (2) hospital-based weight management or bariatric programs; (3) telehealth platforms with US-licensed clinicians in all 50 states. Telehealth is the fastest pathway (days to 1 week); specialist appointments take 3–16 weeks.

**Is GLP-1 therapy available through telehealth in all 50 US states?**
Yes. GLP-1 medications are not controlled substances, simplifying telehealth prescribing. Licensed platforms operate across all 50 states through networks of US-licensed MDs, DOs, NPs, and PAs. State licensure compliance required.

**How quickly will I start losing weight?**
Most patients notice weight loss within the first 4–8 weeks. Significant clinical weight loss emerges after 12–24 weeks, continues over the first year, plateaus thereafter. Continued therapy is required for maintenance; discontinuation generally leads to partial or full regain.

**Can I take GLP-1 medications if I have type 1 diabetes?**
GLP-1 medications are not FDA-approved for type 1 diabetes. Off-label use outside research is not recommended.

**Can I stop GLP-1 therapy once I reach my goal weight?**
Evidence from STEP-4, SURMOUNT-4, and similar maintenance trials shows substantial weight regain after discontinuation (often within 12–18 months). Obesity is increasingly understood as a chronic disease requiring ongoing management. Taper decisions should be made with the prescriber.

**Can I use GLP-1 medications during pregnancy?**
No. Not recommended during pregnancy due to animal studies showing fetal harm and insufficient human data. Contraception counseling is standard. Discontinuation at least 2 months before planned conception recommended.

**How do GLP-1 medications affect birth control pills?**
Delayed gastric emptying can reduce effectiveness of oral hormonal contraceptives during initiation and dose escalation. Use an additional non-oral contraceptive method for 4 weeks after starting and 4 weeks after each dose escalation.

**Is GLP-1 therapy safe long-term?**
Safety data extend to approximately 3–5 years from clinical trials, with ongoing surveillance. No long-term safety concerns beyond labeled warnings have been identified as of 2026. Wegovy's SELECT cardiovascular outcomes trial (NEJM 2023) and SURMOUNT-MMO (ongoing) are establishing extended safety profiles.

**Can I inject GLP-1 medications at home?**
Yes. All weekly injectable GLP-1 medications are self-administered via pre-filled pen (subcutaneous injection). Daily injections (Saxenda) are also self-administered. Patient education on technique, rotation, and storage is standard.

**Are GLP-1 medications approved for cardiovascular disease?**
Wegovy (semaglutide) is FDA-approved for cardiovascular risk reduction in overweight/obese adults with established CVD (March 2024), based on SELECT trial results. This led to Medicare Part D coverage for CVD patients. Tirzepatide's cardiovascular outcomes trials (SURPASS-CVOT, SURMOUNT-MMO) are ongoing with readouts expected 2026–2027.

**Can I use GLP-1 medications for obstructive sleep apnea?**
Zepbound (tirzepatide) received FDA approval in December 2024 for moderate-to-severe OSA in adults with obesity. This indication expanded insurance coverage for qualifying patients. Other GLP-1 medications are not specifically FDA-approved for OSA.

**What's the difference between Ozempic, Wegovy, and Rybelsus?**
All three contain semaglutide. Ozempic is FDA-approved for T2D (weekly injection). Wegovy is FDA-approved for chronic weight management and CV risk reduction (weekly injection, higher max dose). Rybelsus is FDA-approved for T2D only (daily oral tablet). Insurance coverage rules differ significantly.

**What's the difference between Mounjaro and Zepbound?**
Both contain tirzepatide. Mounjaro is FDA-approved for T2D; Zepbound is FDA-approved for chronic weight management and OSA. Pens are technically similar; labeling, patient education, insurance rules, and pricing differ.

**Are Wegovy and Zepbound the same?**
No. Wegovy contains semaglutide (GLP-1 mono-agonist, Novo Nordisk). Zepbound contains tirzepatide (dual GIP/GLP-1 agonist, Eli Lilly). Both are FDA-approved for chronic weight management with similar eligibility criteria but different mechanisms, slightly different efficacy and side effect profiles, and different manufacturers.

**Do I need to diet while taking GLP-1 medications?**
The FDA label specifies use "as an adjunct to a reduced-calorie diet and increased physical activity." Clinical trial results were obtained in the context of lifestyle counseling. Lifestyle change is not optional for optimal and durable results.

**How long do the effects last after discontinuation?**
Clinical effects diminish as medication clears (half-life ~5–7 days for weekly injectables). Weight loss maintenance requires continued therapy; most patients regain substantial weight within 12–18 months after discontinuation, per STEP-4, SURMOUNT-4, and similar studies.

**Is GLP-1 therapy available without a prescription?**
No. All GLP-1 medications are prescription-only in the US. Purchasing from sources not requiring a prescription is illegal, unsafe, and often involves counterfeit or adulterated products.

**Can I drink alcohol while taking GLP-1 medications?**
No specific contraindication, but alcohol may exacerbate GI side effects, increase hypoglycemia risk (with insulin/sulfonylureas), and complicate pancreatitis risk. Moderation advised.

**What if I miss a dose?**
For weekly injectables, if within ~4–5 days of the scheduled dose, inject as soon as remembered. Beyond that window, skip and resume normal schedule. Never double-dose. For daily medications (Rybelsus, Saxenda), skip the missed dose entirely if it is almost time for the next.

**Can GLP-1 medications be combined with other weight loss medications?**
Not typically. Combining two GLP-1 agonists is not recommended. Combination with phentermine, bupropion-naltrexone, or metformin may be considered by specialists in specific cases but is off-label.

**What's the best alternative if I cannot access GLP-1?**
Depends on goals and eligibility. For T2D: non-GLP-1 options (metformin, SGLT2 inhibitors, insulin). For weight loss without GLP-1 access: phentermine (~$15–40/month), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave). For BMI ≥ 35 with comorbidities: bariatric surgery (sleeve gastrectomy, gastric bypass).

**How do GLP-1 medications compare to bariatric surgery?**
GLP-1 therapy (up to 20–22% weight loss) approaches sleeve gastrectomy efficacy (60–70% excess weight loss ≈ 25–30% total body weight) but is fully reversible. Surgery is more durable long-term but invasive, with 6–12 month insurance-mandated preparation. Combination approaches (surgery + GLP-1) are increasingly common.

**What time of day should I inject GLP-1 medications?**
Any time, with or without food. No pharmacologic reason to inject at a specific hour. Consistency helps — select a weekly day and time, stick to it.

**How should I store GLP-1 pens?**
Unopened: refrigerate (36°F–46°F). Opened or at room temperature: up to 21 days (varies by brand — check package insert) up to 86°F. Do not freeze. Travel: insulated case with cold pack.

**Is GLP-1 therapy safe for people over 65?**
Yes, with monitoring. No dose adjustment based on age. Older adults may be more sensitive to GI side effects; more frequent follow-up standard. Polypharmacy interactions with insulin and sulfonylureas common and require monitoring.

**Is GLP-1 therapy safe for people with kidney disease?**
Yes, with caution. No dose adjustment for mild to severe impairment. Severe GI side effects can precipitate acute kidney injury via dehydration. Limited data in end-stage renal disease.

**Can I take GLP-1 medications together with Ozempic or Wegovy?**
No. Concurrent use of two GLP-1 receptor agonists is not recommended. Mechanisms overlap without additive benefit; side effect risk increases. Transitioning between them requires prescriber guidance.

**Do GLP-1 medications affect other prescription medications?**
Yes. Delayed gastric emptying can alter absorption of oral medications (warfarin, levothyroxine, digoxin, hormonal contraceptives). Insulin and sulfonylureas require dose reduction due to hypoglycemia risk. Always inform prescribers of all medications.

**How many GLP-1 medications are FDA-approved in the United States?**
As of 2026, six active molecules: exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, and generic liraglutide (approved June 2024 for T2D). Multiple investigational agents (retatrutide, orforglipron, cagrilintide-semaglutide) are in Phase 3 trials.

**Which GLP-1 is most effective for weight loss in 2026?**
Tirzepatide (Zepbound) produced the greatest weight loss in clinical trials: 20.9% average at 15 mg over 72 weeks (SURMOUNT-1). Semaglutide (Wegovy) achieved 14.9% average at 2.4 mg over 68 weeks (STEP-1). In a head-to-head trial (SURMOUNT-5), tirzepatide was significantly superior.

**Which GLP-1 is most effective for type 2 diabetes?**
Tirzepatide (Mounjaro) produces the greatest HbA1c reduction among current GLP-1 medications (~2.0–2.4%), followed by semaglutide (~1.5–1.8%). Tirzepatide's dual GIP/GLP-1 mechanism explains this superiority. CV outcomes data are more mature for semaglutide and older GLP-1s.

**Which GLP-1 has cardiovascular risk reduction approval?**
**Wegovy (semaglutide 2.4 mg)** is the only GLP-1 currently FDA-approved for cardiovascular risk reduction in overweight/obese adults with established cardiovascular disease (March 2024, based on SELECT trial). Several GLP-1s (Ozempic, Victoza, Trulicity) have demonstrated CV benefit in T2D trials but are not specifically CV-indicated.

**Are all GLP-1 medications the same class?**
All six molecules are GLP-1 receptor agonists, but tirzepatide is additionally a GIP agonist (dual mechanism). All share similar side effect profiles (GI), similar contraindications (MTC/MEN 2), and similar pharmacologic approaches. The magnitude of effect and duration of action differ significantly.

**How do I choose between Wegovy and Zepbound?**
Both are FDA-approved for chronic weight management with similar eligibility criteria. **Zepbound** produces greater weight loss on average (20.9% vs 14.9%) and has OSA approval. **Wegovy** has an approved CV indication and a longer safety track record. Insurance coverage and prescriber preference often dominate the choice.

**How do I choose between Ozempic and Mounjaro for T2D?**
**Mounjaro** produces greater HbA1c reduction (~2.0–2.4% vs 1.5–1.8% for Ozempic). **Ozempic** has more mature CV outcomes data. Insurance formulary tier and step therapy rules typically drive the practical choice. Both are once-weekly injections.

**Is there a generic GLP-1 available?**
Yes — generic liraglutide for T2D was FDA-approved in June 2024. Generic Saxenda (liraglutide for weight management) is not yet available. Brand semaglutide and tirzepatide are patent-protected until approximately 2031–2032 and beyond.

**What are investigational GLP-1s and when might they be approved?**
Retatrutide (Eli Lilly's triple agonist), orforglipron (Eli Lilly's oral non-peptide GLP-1), and CagriSema (Novo Nordisk's cagrilintide + semaglutide) are in Phase 3. FDA submission expected 2026–2028 depending on trial results. Phase 2 data suggest weight loss of 20–24% for retatrutide.

**Is Trulicity as effective as Ozempic or Mounjaro?**
Trulicity (dulaglutide) is a once-weekly GLP-1 approved for T2D with moderate efficacy (~1.3% HbA1c reduction) and CV benefit (REWIND trial). It is generally less potent than Ozempic or Mounjaro but is well-tolerated and widely covered by insurance.

**Can I switch between different GLP-1 medications?**
Yes, under prescriber guidance. A washout period is typically not required. The prescriber may adjust the starting dose of the new medication based on previous exposure. Insurance re-authorization may be required.

**Which GLP-1 has the lowest cost in 2026?**
Generic liraglutide for T2D (approved June 2024) is the lowest-cost branded GLP-1. Trulicity and Victoza brand versions are next. Semaglutide and tirzepatide brands remain at premium pricing until patent expiration. Manufacturer savings cards significantly reduce costs for commercially insured patients.

## Glossary

- **ABOM**: American Board of Obesity Medicine, the US certification body for obesity medicine specialists.
- **503A pharmacy**: state-licensed compounding pharmacy for individual prescriptions, under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- **503B outsourcing facility**: FDA-registered compounding facility for larger quantities, under Section 503B, subject to cGMP.
- **BMI (Body Mass Index)**: weight (kg) / height² (m²).
- **Compounded medication**: pharmacy-prepared, not FDA-approved, not reviewed by the FDA.
- **CVD (Cardiovascular disease)**: conditions affecting the heart and blood vessels.
- **Dual agonist**: medication that activates two distinct receptors. Tirzepatide is a GIP/GLP-1 dual agonist.
- **FDA**: US Food and Drug Administration.
- **GIP**: glucose-dependent insulinotropic polypeptide.
- **GLP-1**: glucagon-like peptide-1.
- **HbA1c**: glycated hemoglobin, a 3-month blood glucose average.
- **Incretin**: gut hormone (GIP, GLP-1) amplifying insulin secretion in response to oral glucose.
- **Medicare Part D**: Medicare prescription drug coverage.
- **Medicaid**: joint federal-state health coverage program for eligible low-income individuals.
- **Mounjaro**: Eli Lilly brand name for tirzepatide for T2D (FDA 2022).
- **Ozempic / Wegovy / Rybelsus**: Novo Nordisk brand names for semaglutide (T2D / weight mgmt / oral T2D).
- **OSA**: obstructive sleep apnea.
- **Prior authorization (PA)**: insurance requirement for prescriber documentation before coverage.
- **Step therapy**: insurance requirement to try less expensive alternatives first.
- **STEP**: Novo Nordisk's clinical trial program for semaglutide in weight management.
- **SURMOUNT**: Eli Lilly's clinical trial program for tirzepatide in weight management.
- **SURPASS**: Eli Lilly's clinical trial program for tirzepatide in T2D.
- **Titration**: gradual dose escalation to improve tolerability.
- **Zepbound**: Eli Lilly brand name for tirzepatide for weight management (FDA 2023) and OSA (FDA 2024).

## Official Sources 2026

All data in this document are drawn from or cross-referenced against the following primary US sources:

- [US Food and Drug Administration (FDA)](https://www.fda.gov/drugs/drug-approvals-and-databases) — FDA approval histories and label information.
- [FDA Drug Shortage Database](https://www.accessdata.fda.gov/scripts/drugshortages/) — current shortage status for semaglutide and tirzepatide.
- [FDA — Human Drug Compounding](https://www.fda.gov/drugs/human-drug-compounding) — regulatory framework for 503A and 503B compounding.
- [Centers for Medicare & Medicaid Services (CMS)](https://www.cms.gov/) — Medicare and Medicaid coverage policy.
- [Medicare.gov — Drug Coverage Search](https://www.medicare.gov/plan-compare/) — plan-specific formulary lookup.
- [DailyMed (NIH / NLM)](https://dailymed.nlm.nih.gov/) — official FDA package inserts.
- [ClinicalTrials.gov](https://clinicaltrials.gov/) — registry of SURMOUNT, SURPASS, STEP, SELECT, and other trials.
- [The New England Journal of Medicine](https://www.nejm.org/) — primary publication venue for SURMOUNT, STEP, SELECT.
- [JAMA — The Journal of the American Medical Association](https://jamanetwork.com/) — publication venue for STEP-3, STEP-4, SURMOUNT-4.
- [American Diabetes Association Standards of Care](https://diabetesjournals.org/care) — annually updated clinical guidelines.
- [American Heart Association — Scientific Statements](https://www.heart.org/) — cardiovascular clinical guidelines.
- [Obesity Medicine Association](https://obesitymedicine.org/) — clinical practice guidance.
- [American Board of Obesity Medicine (ABOM)](https://www.abom.org/) — certification directory.

## Additional Resources

- [Novo Nordisk — Ozempic patient site](https://www.ozempic.com/) — official T2D patient information.
- [Novo Nordisk — Wegovy patient site](https://www.wegovy.com/) — official weight management patient information.
- [Eli Lilly — Mounjaro patient site](https://www.mounjaro.com/) — official T2D patient information.
- [Eli Lilly — Zepbound patient site](https://zepbound.lilly.com/) — official weight management patient information, LillyDirect Self Pay.
- [GoodRx](https://www.goodrx.com/) — verified current retail pharmacy pricing.
- [Mark Cuban Cost Plus Drugs](https://costplusdrugs.com/) — direct-purchase pharmacy for select medications.
- [Medicare Plan Finder](https://www.medicare.gov/plan-compare/) — plan-by-plan drug coverage lookup.
- [NIH MedlinePlus](https://medlineplus.gov/) — consumer drug information.

## About This Page

glp-1-near-me.com is a free information and matching platform offering class-wide comparison of GLP-1 receptor agonist medications in the United States. The platform connects eligible US-based patients with licensed telehealth providers, endocrinologists, and obesity medicine specialists capable of recommending the GLP-1 most appropriate for each individual's clinical context. The platform does not manufacture, prescribe, dispense, or sell medications and is not a healthcare provider.

**FDA Disclaimer**: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Compounded preparations referenced in this document are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. GLP-1 receptor agonists are prescription medications. Consult a licensed healthcare provider before initiating therapy. Individual results vary.

Last updated: April 2026.